Journal of Bioequivalence & Bioavailability

Effect of Atorvastatin and Vitamin D on Rheumatoid Arthritis in experimental animals

6^th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit

August 17-19, 2015 Chicago, USA

Omnia Magdy Mohammed

Posters-Accepted Abstracts: J Bioequiv Availab

Abstract:

Rheumatoid arthritis (RA) is the most common chronic systemic, immune-mediated inflammatory disorder that attacks flexible
joints and also may affect many tissues and organs. The present study was designed to assess the effect of atorvastatin and
vitamin D on RA and to compare it with that of methotrexate in female Wistar albino rats. Rheumatoid arthritis was induced by
subcutaneous injection of Complete Freund’s Adjuvant (CFA). Seventy rats were divided into (7) groups, each of 10 rats. Group I was
kept as control. Group II was injected with 0.4 ml CFA for 12 days. Group III, IV and V were injected with CFA then treated with
methotrexate, atorvastatin and vitamin D, respectively. Group VI and VII were injected with CFA then treated with atorvastatin plus
methotrexate; vitamin D plus methotrexate, respectively. Blood samples were collected after four weeks of the last dose of treatment
for hematological examination. Serum samples were used for detection of inflammatory markers and lipid profile. A significantly
increase of total leucocytes, neutrophils, lymphocytes, serum tumor necrosis factor α (TNFα), interleukine-6 (IL-6), total cholesterol
(TC), triglycerides (TGs) and low density lipoprotein cholesterol (LDL) were observed in arthritis rats with significant decrease
in high density lipoprotein cholesterol (HDL). Treatment with atorvastatin and vitamin D significantly decrease TNF α, IL-6 and
modulate the leukocytosis and lipid abnormalities comparable to that exerted by methotrexate. The combination therapy was even
better than each drug alone and is promising for further clinical trials.